• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

A New Zika Treatment Could Come From Head Lice Medicine

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
September 23, 2016, 12:00 PM ET
Stinging Mosquito
Macro Photo of Stinging MosquitoGetty Images/iStockphoto

There were more than 3,300 Zika cases in U.S. states as of September 21, including 43 that were locally acquired in Florida. Congress has yet to pass a funding bill to fight the birth defect-causing pathogen and the mosquitoes which carry them. And a vaccine is still a long ways from the market.

But new progress could come from an unlikely place. Dr. Mariano Garcia-Blanco of the University of Texas Medical Branch tells Fortune that a number of FDA-approved drugs could be effective Zika treatments. Garcia-Blanco and a team of researchers recently released a study finding that at least 20 treatments already on the market show promise, including ivermectin, a common head lice medicine. Also promising: mycophenolic acid (MPA), used to prevent rejection in organ transplantation, and daptomycin, a type of antibiotic.

Read more: Why the Zika Virus Is a Good Thing for Condom Makers

The findings are preliminary, though. More studies need to be done on these drugs’ potential against Zika—especially since their use on pregnant women needs to be balanced with possible harmful side effects, Garcia-Blanco says.

For more, watch this video:

A version of this article appears in the October 1, 2016 issue of Fortune with the headline “Could Decades-Old Drugs Lead to a Cure for Zika?”

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.